BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Raphael CE, Finegold JA, Barron AJ, Whinnett ZI, Mayet J, Linde C, Cleland JG, Levy WC, Francis DP. The effect of duration of follow-up and presence of competing risk on lifespan-gain from implantable cardioverter defibrillator therapy: who benefits the most? Eur Heart J 2015;36:1676-88. [DOI: 10.1093/eurheartj/ehv102] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 3.1] [Reference Citation Analysis]
Number Citing Articles
1 Russian Society of Cardiology (RSC) (. 2020 Clinical practice guidelines for Chronic heart failure. Russ J Cardiol 2020;25:4083. [DOI: 10.15829/1560-4071-2020-4083] [Cited by in Crossref: 63] [Cited by in F6Publishing: 13] [Article Influence: 31.5] [Reference Citation Analysis]
2 Escande W, Boveda S, Defaye P, Leclercq C, Sadoul N, Perier M, Deharo J, Fauchier L, Marijon E, Piot O. Outcomes in Guideline-Based Versus Off-Guideline Primary Prevention Implantable Cardioverter-Defibrillator Recipients. Journal of the American College of Cardiology 2017;70:1302-3. [DOI: 10.1016/j.jacc.2017.07.711] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
3 Manolis AS, Maounis T, Koulouris S, Vassilikos V. "Real life" longevity of implantable cardioverter-defibrillator devices. Clin Cardiol 2017;40:759-64. [PMID: 28543134 DOI: 10.1002/clc.22729] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
4 Chatterjee NA, Borgquist R, Chang Y, Lewey J, Jackson VA, Singh JP, Metlay JP, Lindvall C. Increasing sex differences in the use of cardiac resynchronization therapy with or without implantable cardioverter-defibrillator. Eur Heart J 2017;38:1485-94. [PMID: 28065904 DOI: 10.1093/eurheartj/ehw598] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
5 Lüscher TF, Bax JJ, Gersh BJ, Hindricks G, Landmesser U, Ruschitzka F, Wijns W. EHJ's new impact factor of 15.2: a global strategy is paying off. Eur Heart J 2015;36:2763-6. [PMID: 26745818 DOI: 10.1093/eurheartj/ehv504] [Reference Citation Analysis]
6 Buckley U, Shivkumar K. Implantable cardioverter defibrillators: even better than we thought? Eur Heart J 2015;36:1646-8. [PMID: 25943537 DOI: 10.1093/eurheartj/ehv158] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
7 Mcdonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JG, Coats AJ, Crespo-leiro MG, Farmakis D, Gilard M, Heyman S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CS, Lyon AR, Mcmurray JJ, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GM, Ruschitzka F, Skibelund AK. Guía ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica. Revista Española de Cardiología 2022. [DOI: 10.1016/j.recesp.2021.11.027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A; Authors/Task Force Members:., ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2022;24:4-131. [PMID: 35083827 DOI: 10.1002/ejhf.2333] [Cited by in Crossref: 124] [Cited by in F6Publishing: 33] [Article Influence: 124.0] [Reference Citation Analysis]
9 Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129-2200. [PMID: 27206819 DOI: 10.1093/eurheartj/ehw128] [Cited by in Crossref: 8101] [Cited by in F6Publishing: 6454] [Article Influence: 1350.2] [Reference Citation Analysis]
10 Tereshchenko SN, Zhirov IV, Uskach TM, Saidova MA, Golitsyn SP, Gupalo EM, Nasonova SN, Narusov OY, Safiullina AA, Tereshchenko AS, Stukalova OV. EURASIAN ASSOCIATION OF CARDIOLOGY (EAC)/ NATIONAL SOCIETY OF HEART FAILURE AND MYOCARDIAL DISEASE (NSHFMD) GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF CHRONIC HEART FAILURE (2020). Evrazijskij kardiologičeskij žurnal 2020. [DOI: 10.38109/2225-1685-2020-3-6-76] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González-juanatey JR, Harjola V, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; Authors/Task Force Members, Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the spec. Eur J Heart Fail 2016;18:891-975. [DOI: 10.1002/ejhf.592] [Cited by in Crossref: 3626] [Cited by in F6Publishing: 3057] [Article Influence: 604.3] [Reference Citation Analysis]
12 Lüscher TF. Mitral valve disease, atrial fibrillation, and device therapy. Eur Heart J 2015;36:1631-3. [PMID: 26152588 DOI: 10.1093/eurheartj/ehv225] [Reference Citation Analysis]
13 Balmain S, Hawkins NM. Shocks, Resynchronization, or Both for Elderly Patients With Heart Failure? Journal of Cardiac Failure 2016;22:150-2. [DOI: 10.1016/j.cardfail.2015.12.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
14 Hawkins NM, Osmanska J, Petrie MC. Implantable cardioverter-defibrillators and survival - the fine line between efficacy concerns and ageism. Eur J Heart Fail 2020;22:868-70. [PMID: 32227573 DOI: 10.1002/ejhf.1803] [Reference Citation Analysis]
15 Wang CC, Wu CK, Tsai ML, Lee CM, Huang WC, Chou HH, Huang JL, Chi NH, Yen HW, Tzeng BH, Chang WT, Chang HY, Wang CH, Lu YY, Tsai JP, Su CH, Cherng WJ, Yin WH, Tsai CT, Wu YW, Lin JL, Hwang JJ. 2019 Focused Update of the Guidelines of the Taiwan Society of Cardiology for the Diagnosis and Treatment of Heart Failure. Acta Cardiol Sin 2019;35:244-83. [PMID: 31249457 DOI: 10.6515/ACS.201905_35(3).20190422A] [Cited by in F6Publishing: 18] [Reference Citation Analysis]
16 Schleifer JW, Shen W. Implantable Cardioverter-Defibrillator Implantation, Continuation, and Deactivation in Elderly Patients. Curr Geri Rep 2017;6:279-89. [DOI: 10.1007/s13670-017-0226-9] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
17 Spitzer SG, Andresen D, Kuck KH, Seidl K, Eckardt L, Ulbrich M, Brachmann J, Gonska BD, Hoffmann E, Bauer A, Hochadel M, Senges J. Long-term outcomes after event-free cardioverter defibrillator implantation: comparison between patients discharged within 24 h and routinely hospitalized patients in the German DEVICE registry. Europace 2017;19:968-75. [PMID: 27353325 DOI: 10.1093/europace/euw117] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Saxena S, Goldenberg I, McNitt S, Hsich E, Kutyifa V, Bragazzi NL, Polonsky B, Aktas MK, Huang DT, Rosero S, Klein H, Zareba W, Younis A. Sex Differences in the Risk of First and Recurrent Ventricular Tachyarrhythmias Among Patients Receiving an Implantable Cardioverter-Defibrillator for Primary Prevention. JAMA Netw Open 2022;5:e2217153. [PMID: 35699956 DOI: 10.1001/jamanetworkopen.2022.17153] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Cleland JGF, Mareev Y. CRT for Heart Failure and ESRD: More Trials or More Thought Needed? J Am Coll Cardiol 2015;66:2630-2. [PMID: 26670063 DOI: 10.1016/j.jacc.2015.10.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
20 Raafs AG, Linssen GCM, Brugts JJ, Erol-Yilmaz A, Plomp J, Smits JPP, Nagelsmit MJ, Oortman RM, Hoes AW, Brunner-LaRocca HP. Contemporary use of devices in chronic heart failure in the Netherlands. ESC Heart Fail 2020;7:1771-80. [PMID: 32395914 DOI: 10.1002/ehf2.12740] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599-726. [PMID: 34447992 DOI: 10.1093/eurheartj/ehab368] [Cited by in Crossref: 209] [Cited by in F6Publishing: 73] [Article Influence: 209.0] [Reference Citation Analysis]
22 Hawkins NM, Grubisic M, Andrade JG, Huang F, Ding L, Gao M, Bashir J. Long-term complications, reoperations and survival following cardioverter-defibrillator implant. Heart 2018;104:237-43. [PMID: 28747313 DOI: 10.1136/heartjnl-2017-311638] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]